|
Dynavax Technologies Corporation - Comparative Business Analysis Snapshot
Business Description
Dynavax Technologies Corporation. The Company's principal activity is to discover, develop and commercialize TLR-9 agonist-based products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases. The clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. The products in pipeline includes: TOLAMBA, a ragweed allergy immunotherapeutic, currently in major large-scale clinical trial in ragweed allergic adults and in a supportive trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine, currently in a Phase 3 clinical trial; SUPERVAX, a hepatitis B vaccine; a cancer therapy currently in a Phase 2 clinical trial in non-Hodgkins lymphoma; an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial and preclinical programs in hepatitis B and C therapy.
Competitor Analysis
This analysis compares Dynavax Technologies Corporation with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
